## Abstract Adult mice inoculated with MSV develop tumors, 90% of which undergo immunologically‐mediated regression. Sublethal cyclophosphamide (CY) administered to such tumor‐bearing mice prevented regression, so that 58/60 mice died with tumors. As hosts for immunotherapy, adult BALB/c mice beari
Kinetics of inflammation and sarcoma cell development in primary moloney sarcoma-virus-induced tumors
✍ Scribed by Susanne Becker; Stephen Haskill
- Publisher
- John Wiley and Sons
- Year
- 1981
- Tongue
- French
- Weight
- 597 KB
- Volume
- 27
- Category
- Article
- ISSN
- 0020-7136
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
The kinetics of ‘sarcoma’ cell appearance and inflammatory cell infiltration into primary Moloney sarcoma virus (MSV)‐induced tumors has been studied in normal and partially immunosuppressed anti‐lymphocyte‐globulin (ALG)‐treated A/WySn mice. The ALG treatment facilitated an earlier appearance of gp70‐positive ‘sarcoma’ cells accompanied by an intense inflammatory response. Time course pulse‐labelling studies showed that a decreasing proportion of gp70‐positive ‘sarcoma’ cells were incorporating [^3^H]‐thymidine in vivo in both normal and immunosuppressed mice as the lesion progressed to maximum size. ALG‐treated mice inoculated with MSV were given a single injection of [^3^H]‐thymidine immediately prior to extensive appearance of gp70‐positive ‘sarcoma’ cells (day 6) and were studied for the presence of labelled gp70‐positive cells 2 h, 2 days and 6 days post labelling. The data indicate that few cells divided during the time in which an 8‐ to 10‐fold increase in virus‐positive ‘sarcoma’ cell number occurred. These experiments provide evidence that recruitment rather than proliferation of virus‐positive cells occurred. The results also suggest that, within the tumor, defense mechanisms develop which restrict sarcomacell proliferation also in ALG‐treated mice. The composition of inflammatory cells during the course of tumor progression and regression in the uncompromised mice revealed that the proportion of lymphocytes was highest early and late during tumor development, dropping to a minimum at the peak size of the tumor. Macrophages and granulocytes constituted 70–80% of the total cells recovered at peak tumor size and the onset of regression. In the ALG‐treated mice, the proportions of macrophages, granulocytes, and infrequent lymphocytes remained constant throughout the duration of the tumor progression. A decrease in total cells, including a decrease in gp70‐positive cells, was noticed before a change in the proportion of infiltrating lymphocytes occurred due to recovery of the immune system. The composition of the inflammatory cells at onset of regression suggests that macrophages and granulocytes are of major importance in the defense against MSV infection.
📜 SIMILAR VOLUMES
## Abstract Pre‐treatment of BALB/c mice with an intraperitoneal injection of heat‐inactivated serum obtained from BALB/c mice with progressively growing Moloney‐virus‐induced sarcomas (“progressor” mice) shortens the latent period and increases the growth rate and maximum size of primary sarcomas
## Abstract Tumor induction and immunity to tumors were studied following the injection of Moloney sarcoma virus (MSV) into mice whose B‐lymphocyte functions had been suppressed by the chronic administration of anti‐IgM antibodies. Two preparations of MSV were used; one which gives rise to tumors w
## Abstract Sublethally irradiated BALB/c mice innoculated with Moloney sarcoma virus (MSV‐M) develop progressively growing tumors and die within 30 days of virus innoculation. These animals can be protected from tumor progression (and death) by innoculation of small numbers of MSV‐immune T lymphoc
## Abstract Studies of the MLTI were performed in a primary MSV‐induced tumor system. Reactivity against mitomycin‐C‐treated RBL‐5 cells could be detected during a limited period at about 14 days after virus injection. The degree of reactivity of MSV 14 spleen cells was quite variable; stimulation
## Abstract Macrophages isolated from regressing or progressing tumors induced by murine sarcoma virus (MSV) were tested for cytolytic activity in an 18‐h ^51^Cr release assay. Macrophages from the tumors of mice injected 14 days earlier with stocks of MSV‐producing regressor or progressor tumors h